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Changes in long-range rDNA-genomic interactions
associate with altered RNA polymerase II gene
programs during malignant transformation
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The three-dimensional organization of the genome contributes to its maintenance and reg-
ulation. While chromosomal regions associate with nucleolar ribosomal RNA genes (rDNA),
the biological significance of rDNA-genome interactions and whether they are dynamically
regulated during disease remain unclear. rDNA chromatin exists in multiple inactive and
active states and their transition is regulated by the RNA polymerase I transcription factor
UBTF. Here, using a MYC-driven lymphoma model, we demonstrate that during malignant
progression the rDNA chromatin converts to the open state, which is required for tumor cell
survival. Moreover, this rDNA transition co-occurs with a reorganization of rDNA-genome
contacts which correlate with gene expression changes at associated loci, impacting gene
ontologies including B-cell differentiation, cell growth and metabolism. We propose that
UBTF-mediated conversion to open rDNA chromatin during malignant transformation con-
tributes to the regulation of specific gene pathways that regulate growth and differentiation
through reformed long-range physical interactions with the rDNA.
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Advances in genomics and epigenomics have providedinsights into three-dimensional (3D) genome organiza-tion at an unprecedented level of detail1–3, and highlight
the dynamic relationship between genomic spatial organization
and gene regulation4,5. However, relatively little is understood
about how genome organization and gene expression are
reshaped during disease development and their impact on the
process6. The largest substructure in the nucleus is the nucleolus,
the site of ribosome biogenesis, which forms dynamically around
transcribed ribosomal RNA (rRNA) genes (rDNA) arranged in
arrays of tandem repeats at chromosomal regions called nucleolar
organizer regions (NORs)7. The NORs are organized on acro-
centric chromosomes, with the highly variable rDNA copy
number averaging more than 100 per diploid genome7,8. How-
ever, at any given time less than 50% of these rDNA copies are
actively transcribed by the dedicated RNA polymerase I (Pol I) to
produce the 47S rRNA precursor9. A large body of evidence
supports a model of rDNA copies existing in one of three epi-
genetic chromatin states: silent (CpG methylated at the rDNA
promoter), pseudo-silent (lacking hypomethylated promoters but
transcriptionally inactive), or active (hypomethylated and tran-
scriptionally competent)10. Active genes exhibit a range of tran-
scription rates depending on the cellular state, and the relative
ratio of silent, pseudo-silent and active genes is modulated during
differentiation and development11–15. These states are regulated
epigenetically and via the upstream binding transcription factor
(UBTF), an architectural protein required to recruit Pol I to the
rDNA promoter but also critical for binding to under-methylated,
pseudo-silent rDNA repeats to convert them into the active,
transcriptionally competent state12,14,16,17.
Functions beyond production of rRNA are well documented
for the rDNA and nucleolus, including regulation of genomic
stability and global gene expression18–23. Genomic sequences that
include certain genes other than rDNA are localized to nucleoli in
nucleolar-associated domains (NADs)24–28. The NAD nucleolar
chromatin compartment is enriched for repressive chromatin
marks and under-represented for active histone modifications,
and NAD-associated genes are generally transcriptionally
repressed24–27. This is consistent with evidence that the nucleolus
is surrounded by a facultative heterochromatic shell26,29,30, and
highlights a potential role for the nucleolus in dynamically reg-
ulating global gene transcription through nucleolar colocalization.
The interplay between altered nucleolar morphology and dis-
ease is well recognized and accelerated rRNA transcription and
ribosome biogenesis is a common feature of many cancers31–33.
This is reflected by the increased size and/or number of nucleoli
in tumor cells, initially observed by pathologists over 100 years
ago and used as a diagnostic and prognostic marker for certain
cancers34. Moreover, the potential of dysregulated ribosome
biogenesis as a therapeutic target in cancer has been demon-
strated by the development of small molecule inhibitors of Pol I
transcription35–39. The MYC oncogene, a potent transcriptional
driver of growth-associated gene programs40–42 via all three RNA
polymerases (Pol I, II, and III), has been implicated in sensitizing
MYC-addicted cancer cells to inhibition of Pol I
transcription13,43–48. However, while a substantial body of data
has provided critical insight into our understanding of rDNA as a
therapeutic target36,37,39,49–53, the precise mechanisms under-
lying the heightened sensitivity of tumor cells to perturbations in
Pol I transcription and the degree to which subsequent disruption
of nucleolar integrity contributes to the therapeutic window
remain unresolved.
Here we examine whether changes to rDNA chromatin
structure are associated with malignant transformation and fur-
ther, are accompanied by alterations in rDNA-NAD interactions.
Using the Eµ-Myc mouse model of spontaneous MYC-driven B-
cell lymphoma, we showed that progression from premalignancy
to malignancy in vivo is associated with UBTF-dependent epi-
genetic remodeling that activates a significant proportion of
previously pseudo-silent rDNA repeats. Circularized chromo-
some conformation capture sequencing (4C-seq) demonstrated
that, concomitant with activation of rDNA during malignancy,
the population of genomic loci interacting with the rDNA
changes during lymphomagenesis. Genes associated with these
rDNA-interacting loci show an inverse relationship between their
rDNA interaction level and their gene expression. A sub-
population of the rDNA-NAD interactions that change during
malignant progression require the active chromatin state of the
rDNA repeats. Notably, of this NAD-associated loci sub-popu-
lation, those with reduced expression in malignant cells are
enriched for genes encoding proteins involved in B-cell differ-
entiation. Conversely, those with increased expression are enri-
ched for growth and metabolism gene ontologies. We propose
that malignancy-associated alterations in the rDNA chromatin
status are linked to formation of new rDNA-genomic interactions
and co-occur with gene expression changes that contribute to the
malignant phenotype.
Results
rDNA chromatin opens during Eµ-Mycmalignant progression.
Mice harbouring the Eµ-Myc transgene display abnormal B-cell
development, characterized by an initial premalignant phase in
young mice (4–6 weeks) of enhanced B-cell progenitor prolifera-
tion and growth before eventually progressing to malignant lym-
phoma54–56. Both premalignant and malignant Eµ-Myc B-cells
have elevated rRNA synthesis rates compared to wild-type B cells
of the same developmental stage due to elevated expression levels
of the MYC oncogene37. To investigate the status of rDNA
chromatin with respect to rRNA transcription rates during
malignant progression, we compared their dynamics in wild type,
premalignant, and malignant cells isolated from Eµ-Myc mice. We
separated these changes from variables associated with differ-
entiation status and tumor compartment by performing analyses
on IgM-negative pre-B cell subtypes (B220highIgMlowIgDlow)
FACS sorted from bone marrow (with individual animals as
biological replicates). MYC overexpression induced a robust
increase in rRNA transcription rates in premalignant cells com-
pared to cells from wild-type littermates, with no further sig-
nificant increase observed between premalignant and malignant
cells as measured using qRT-PCR (Fig. 1a) or rRNA fluorescence
in situ hybridization (FISH) (Fig. 1b). We assayed rDNA chro-
matin structure by performing psoralen crosslinking followed by
southern blot analysis. Psoralen preferentially incorporates into
more accessible DNA regions and distinguishes between active
(i.e., transcriptionally competent open rDNA chromatin) and
inactive (i.e., silent and pseudo-silent) rRNA genes11. In contrast
to the elevated rRNA transcription rates in both premalignant and
malignant cells (Fig. 1a, b), the fraction of active rDNA repeats
was significantly elevated in malignant cells only (malignant,
38.2% active vs. premalignant, 16.6% active) (Fig. 1c, d, Supple-
mentary Fig. 1a-d). Furthermore, high ratios of active to inactive
rDNA chromatin were uniformly observed in lymphoma cell lines
established from independent Eµ-Myc tumors (lymphoma lines
average, 42.8% active) as compared to wild type and premalignant
cells (Fig. 1d, e). Thus, changes in the ratio of active to inactive
rDNA repeats specifically occur as cells transition from pre-
malignant to malignant and are uncoupled from MYC-driven
rRNA transcription rates during malignant progression.
Loading of the Pol I architectural factor UBTF (consisting of two
polypeptides, UBTF1 and 2) onto rDNA is required for the
formation and maintenance of active, transcriptionally competent
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rDNA12,17,57. Therefore, we used quantitative ChIP to determine
UBTF enrichment at rDNA in all stages of Eµ-Myc pre-B cells.
Consistent with the psoralen results, UBTF enrichment was
significantly increased in malignant cells compared to premalignant
cells (Fig. 1f), with a modest increase in premalignant cells over wild
type. These results suggest that UBTF binding at rDNA mediates
the conversion of rDNA to the active chromatin state as cells
transition from premalignancy to malignancy and this occurs in the
absence of further increase in the rRNA transcription rate.
While CpG dinucleotide methylation of the rDNA promoter
core region is implicated in silencing of murine rDNA14,58, we
previously demonstrated that UBTF regulates the transition from
pseudo-silent to open rDNA chromatin in the absence of this
methylation12,13. To investigate the methylation status at the
rDNA promoter compared to the rDNA chromatin state, we
performed methylation-sensitive digestion at the −143 CCGG
HpaII site of genomic DNA from wild type, premalignant, and




















































































































































Fig. 1 rDNA chromatin undergoes remodeling as Eμ-Myc cells transition to malignancy. a Relative pre-rRNA expression (rRNA transcription rate) in wild
type (wt), premalignant (prem) and malignant (mal) Eμ-Myc cells determined by qRT-PCR using primers to the rapidly degraded 5’ external transcribed
spacer (5’ETS) region. Pre-rRNA levels were normalized to B2M mRNA and represented relative to wt (x ± s.e.m., n= 3 mice/cell stage). b rRNA levels in
cells from a as determined by rRNA FISH using a probe (red) to the degraded internal transcribed spacer (ITS1) region. Nuclei were counterstained with
DAPI (blue). Scale bars, 10 μm. c Representative Southern blot of psoralen cross-linked genomic rDNA from wt, prem and mal Eμ-Myc cells; arrows indicate
active and inactive rDNA repeats. d Four independent psoralen Southern blot experiments as in c were quantitated with ImageQuant (x ± s.e.m., n= 4).
Also shown is quantitation (lines) of e Southern blot of psoralen cross-linked genomic rDNA from Eμ-Myc lymphoma cells lines (lane 1: no psoralen control,
4242 line; lanes 2–5: lines 226, 107, 4242, and 102); arrows indicate active and inactive rDNA repeats. f ChIP analysis of UBTF binding at the rDNA
promoter (CORE) and transcribed (28S) regions. The percentage (%) of DNA immunoprecipitated with anti-UBTF or rabbit sera (RS) was calculated
relative to the unprecipitated input control and the % of DNA associated with RS was subtracted from corresponding UBTF samples (x ± s.e.m., n= 3).
g CpG methylation at the rDNA core promoter determined by HpaII digestion followed by qPCR of total rDNA (left panel) and UBTF-bound rDNA (right
panel). The percentage of unmethylated and methylated rDNA is plotted (x ± s.d., total rDNA n= 3, UBTF ChIP-CHOP n= 2). h CpG methylation frequency
across the rDNA unit determined by methylated DNA immunoprecipitation (MeDIP) followed by qPCR using amplicons spanning the rDNA repeat. All
amplicon primers as labeled except: 5’ETS (ETS1), 28S (28S-2), and IGS (IGS2). Samples are analyzed by qPCR with results expressed as percent (%) of
total DNA (minus RS % total) as described in f (x ± s.d., n= 2). The Student's t-test was used for all statistical analyses: *p-value < 0.05; **p-value < 0.01;
***p-value < 0.001; NS, not significant
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and the adjacent −133 CpG methylated residue at the rDNA
promoter12,59. We detected no significant change in methylation
at the −143 CpG (Fig. 1g, left), despite the striking shift in rDNA
chromatin status during malignant progression (Fig. 1c, d).
Similarly, we did not identify any significant changes in
enrichment of CpG methylation at amplicons spanning the
rDNA unit between cell types using quantitative methylated DNA
immunoprecipitation (qMeDIP) (Fig. 1h). These findings indicate
that the switch from inactive to active rDNA state during the
transition to malignancy does not correlate with changes in
rDNA CpG methylation. Because UBTF binding is associated
with active rDNA repeats, we examined the methylation status of
UBTF-bound regions by performing UBTF ChIP followed by
HpaII digestion and qPCR at the −143 CpG site (ChIP-CHOP),
and found that the majority of UBTF-bound rDNA (~80%) was
unmethylated in all cell stages (Fig. 1g, right). Collectively, these
results demonstrate that the MYC-driven premalignant state,
compared to wild type, is characterized by increased rRNA
production without major alterations in the rDNA chromatin
state. In contrast, the transition to malignancy is accompanied by
the UBTF-associated activation of pseudo-silenced rDNA
(termed herein rDNA class switching), which is uncoupled from
changes in rRNA transcription rates.
Eµ-Myc lymphoma survival requires UBTF-mediated active
rDNA. Given the observation that clonal Eμ-Myc lymphomas
show significantly elevated ratios of active rDNA repeats, we
hypothesised that rDNA class switching is favorable to the
malignant state. To test this, we investigated whether tumor cell
survival is dependent on the elevated active:inactive rDNA ratio
independent of rRNA transcription rate. We previously estab-
lished that Ubtf knockdown leads to a reduction in the number of
active rDNA repeats without affecting overall rRNA transcription
rate due to compensatory mechanisms that maintain rRNA
synthesis at a constant level12. Here, we confirmed this observa-
tion using a shRNAmiR targeting Ubtf (Ubtf1/2)37 in an Eμ-Myc
lymphoma cell line (Eμ-Myc-shUbtf). Knockdown of Ubtf led to a
robust reduction of UBTF compared to control cell line (Eμ-Myc-
LMP) (Fig. 2a) that was accompanied by a pronounced reduction
in active rDNA repeats (Fig. 2b) but only a modest reduction in
relative rRNA transcription rates (Fig. 2c, d).
To investigate whether the reversal of rDNA class switching by
Ubtf knockdown impacts cell proliferation and survival, we used
an in vitro GFP-based cell competition assay37. Mock-transduced
Eμ-Myc lymphoma cells were seeded in culture with equal
numbers of cells retrovirally transduced with either empty vector
or shUbtf expressing vector, and survival of the vector-driven GFP
expressing cells was monitored by FACS. Long-term (8 days)
competition revealed that shUbtf-expressing cells have an acute
survival disadvantage compared to control cells (Fig. 2e). More-
over, this survival handicap was only partially rescued by
overexpression of the anti-apoptotic factor BCL2. In comparison,
we performed knockdown of the Pol I transcription initiation
factor RRN3 (shRrn3)37, which leads to reduced rRNA transcrip-
tion but does not regulate rDNA chromatin remodelling57. Rrn3
knockdown also resulted in a proliferation disadvantage compared
to control cells, but unlike Ubtf knockdown, the cell death in
response to RRN3 loss was completely rescued by BCL2
overexpression (Fig. 2e). This is consistent with our previous
data showing that Eμ-Myc lymphoma cells treated with CX-5461,
a highly selective inhibitor of Pol I-mediated transcription36, are
over 100-fold less sensitive to apoptotic cell death following BCL2
overexpression37. CX-5461 inhibits rDNA transcription by
preventing recruitment of the transcription competent Pol I
complex (including RRN3) while minimally perturbing UBTF
association with the rDNA51. Following treatment of lymphoma
cells with CX-5461, we observed no significant change to the ratio
of active to inactive rDNA despite repression of rRNA transcrip-
tion (Supplementary Fig. 2). Taken together, these data indicate
that survival of malignant Eμ-Myc cells is dependent on the ability
of UBTF to maintain an active rDNA chromatin state indepen-
dent of the rRNA transcription rate.
rDNA repeats engage in long-range chromatin interactions.
The observation that the rDNA chromatin status affects tumor
cell survival independent of rRNA transcription rate per se sug-
gests that changes in rDNA chromatin might impart functional
effects. Non-rDNA-genomic regions, called NADs, localize to the
nucleolus, which forms around actively transcribed rDNA
repeats24–28. Changes in rDNA structure/activity can influence
genome-wide chromatin structure and gene expression19,20,
therefore we examined whether rDNA class switching promotes
reorganization of NADs. We used 4C-seq to identify long-range
chromatin interactions that occur with rDNA sequences during
lymphomagenesis. Multiple bait sequences located in the tran-
scribed 18S and 28S rDNA regions (Fig. 3a) were used to capture
interactions between the rDNA and rest of the genome in isolated
wild type, premalignant, and malignant pre-B cells. Cell-type
specific rDNA interactions were included in subsequent analyses
if they were observed in two biological replicates (i.e., animals).
We combined all replicated rDNA interactions for each cell type
and calculated the average read count per interaction in 5-kb
non-overlapping windows as a semi-quantitative measure of
interaction frequency (read counts listed in Supplementary
Data 1). The interactions were not restricted to a few specific loci
and did not show a bias towards the rDNA-containing chro-
mosomes (12, 15, 18, and 19 in the Eμ-Myc C57BL/6 genetic
background60), but were uniformly distributed across all chro-
mosomes (Supplementary Fig. 3a). We categorized the rDNA-
genome interactions into two categories: those that show no
significant change (FDR > 0.1) between wild type, premalignant,
and malignant cells (constitutive rDNA interactions, Supple-
mentary Data 2); and those that are significantly changed (FDR <
0.1) between any pair of cell stages (differential rDNA interac-
tions). We plotted the top 10% of differential rDNA interactions
(regardless of fold-change direction) and while qualitative only,
circos plots revealed that the major overall interaction re-
configuration occurs between premalignant and malignant cells
(Fig. 3b). These results suggest that B-cell lymphomagenesis is
associated with changes in the pattern of interactions that rDNA
forms with the rest of genome.
rDNA-genome interactions correlate with transcriptome
changes. Specific gene families are reported to be enriched within
NAD sequences24,25,27, therefore we sought to characterize
whether this occurred during malignant progression. We deter-
mined the closest gene for each rDNA-interacting fragment based
on the nearest transcription start site (TSS). Analysis of gene
ontologies (GOs) of protein coding genes associated with con-
stitutive rDNA-interacting regions showed an over-
representation of GO terms that comprise zinc finger domain
proteins, transmembrane channel proteins and G-protein-
coupled receptors (Fig. 3c, Table 1 and Supplementary Data 2).
Inspection of all genes mapping to constitutively interacting
regions revealed an enrichment of non-coding RNA (ncRNA)
genes (e.g., small nucleolar RNAs (snoRNAs), spliceosomal small
nuclear RNAs (snRNAs)) and genes encoding olfactory and
vomeronasal receptors (Table 1, Supplementary Data 2). These
results are in keeping with previous studies demonstrating
nucleolar enrichment of specific gene classes including certain
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ncRNAs and zinc finger and olfactory receptor encoding
genes24,25,27. Interestingly, while we detected 5S rRNA pseudo-
genes within the constitutive interaction set, we did not detect any
rDNA interactions with the canonical 5S rRNA array on chro-
mosome 8, consistent with reported Hi-C data28,61.
The nucleolar periphery is characterized by a facultative
heterochromatic shell and transcriptionally inactive regions30,
thus we determined if there is an association between physical
interactions with the rDNA and gene expression. We performed
RNA-seq on wild type, premalignant, and malignant cells and
determined the average gene expression (reads per kilobase of
transcript per million reads mapped [RPKM]) for all genes
(Supplementary Data 3). We compared the density of RPKM
distributions for genes associated with rDNA-interacting (con-
stitutive and differential) and non-interacting regions for all
stages of malignant progression (Fig. 3d). Genes associated with
rDNA-interacting regions (Fig. 3d, red lines) in the premalignant
and malignant cells, but not wild-type cells, had significantly
lower expression levels than non-interacting genes (Fig. 3d, blue
lines). This observation is consistent with previous findings24–27
that association with the rDNA correlates with a repressive effect
on gene expression.
Global gene expression analysis identified 4908 differentially
expressed genes during malignant progression (wild type vs.
malignant cells, FDR ≤ 0.1; −0.5 ≥ logFC ≥ 0.5) (Supplementary
Data 3). We intersected these with the 23,476 rDNA interactions
that changed during progression from premalignant to malig-
nant, coincident with rDNA class switching (Supplementary
Data 4). The majority of differentially expressed genes (3961 out
of 4908 genes) were proximal to differentially interacting regions.
Notably, we observed a robust inverse relationship between
rDNA interaction and gene expression for rDNA-interacting
genes whose expression changes significantly from premalignant
to malignant (746 genes) (Fig. 3e). These results showed a
correlation between interaction with the rDNA and transcrip-
tional repression of associated genes as cells transition from
premalignancy to malignancy, suggesting that rDNA-NAD
interactions contribute to Pol II gene regulation during the
development of malignancy.
UBTF-dependent interactions involve specific gene pathways.
To identify interactions that are reliant upon UBTF-dependent
rDNA class switching as opposed to those that are intrinsically a
consequence of malignant transformation, we performed 4C-seq
in the stable Ubtf knockdown lymphoma cells (Eμ-Myc-shUbtf)
compared to control cells (Eμ-Myc-LMP). Again, the distribution
of the Ubtf-dependent rDNA interactions (Supplementary
Data 5) was spread across all chromosomes (Supplementary
Fig. 3b). rDNA interactions with genomic DNA in mouse
embryonic stem cells (mESCs) have been reported using the
recently developed split-pool recognition of interactions by tag
extension (SPRITE) method62. We interrogated the overlap of
mESCs SPRITE rDNA contacts with our 4C-seq rDNA interac-
tions identified in the Eμ-Myc lymphoma cell lines. This analysis
indicated a strong concurrence between the SPRITE-identified
rDNA hub genomic connections and our 4C rDNA-NAD con-
nections for both the LMP and shUbtf conditions, with bootstrap
samples confirming the non-random nature of the intersection
(Supplementary Fig. 3c). We intersected the rDNA interactions
detected in the Ubtf knockdown cells with those from the Eμ-Myc
pre-B cells and identified reciprocal interactions that either
increase upon premalignant to malignant transition and decrease
with UBTF loss (1822 interactions) or decrease upon pre-
malignant to malignant transition and increase with UBTF loss
(1246 interactions) (Fig. 4a, Supplementary Data 6). These
UBTF-dependent rDNA class switch interactions correlated with
the changes in rDNA chromatin state that occur during transition
to malignancy and are reversed by UBTF knockdown (Fig. 4a).
A substantial fraction (28%: 864 of 3068 total interactions) of
the rDNA class switch interacting regions were located within
5–20 kb of the associated gene’s TSS (Supplementary Fig. 4a).
Considering that changes in rDNA interaction correlated with
altered expression levels of the nearest gene (Fig. 3e), we
examined whether these rDNA-interacting fragments are
enriched for putative regulatory elements by intersecting them
with regions marked by the enhancer-associated H3K4me1
histone modification in Eμ-Myc tumor cells63. Thirteen percent
of loci that differentially interacted with the rDNA during the













































































Fig. 2 UBTF loss in lymphoma cells reduces active rDNA and cell survival independent of rDNA transcription. a Eμ-Myc-Bcl2 cells (4242-Bcl2) were stably
transfected with empty vector LMP (Eμ-Myc-LMP cells) or shUbtf (Eμ-Myc-shUbtf cells) and Ubtf knockdown verified by Western blot of UBTF protein
compared to GAPDH loading control. b Representative Southern blot of psoralen cross-linked genomic rDNA from Eμ-Myc-LMP and Eμ-Myc-shUbtf cells as
in Fig. 1c. c Relative pre-rRNA (47SrRNA) expression in Eμ-Myc-LMP or Eμ-Myc-shUbtf cells determined by qRT-PCR. Pre-rRNA levels were determined as
in Fig. 1a, at 72 h post transduction. RNA levels were normalized to B2M mRNA and are represented relative to Eμ-Myc-LMP (x ± s.e.m., **p-value < 0.01;
n= 3). d rRNA levels in Eμ-Myc-LMP or Eμ-Myc-shUbtf cells determined by rRNA FISH as in Fig. 1b. Scale bars, 10 μm. e GFP competition assay using Eμ-
Myc-LMP, Eμ-Myc-shUbtf, and Eμ-Myc-shRrn3 (shRrn3) cells co-cultured with mock-transduced Eμ-Myc cells either in the absence (−) or presence (+) of
Bcl2 overexpression. Data are expressed as percent fold change in GFP+ cells 8 days post transduction (x ± s.e.m., *p-value < 0.05; **p-value < 0.01; n= 3)
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Fig. 3 rDNA repeats engage in long-range chromatin interactions during lymphomagenesis. a Schematic representation of a representative rDNA repeat
indicating the 4C-seq bait positions sequences listed in Supplementary Table 1). b Circos plots illustrating the top 10% significantly differential interactions
(between a representative 28S rDNA bait and the rest of the genome) in wild type (wt), premalignant (prem) and malignant (mal) Eμ-Myc cells. The
depicted differences in rDNA interactions between cell stages is qualitative only. Interactions with each chromosome are highlighted in a different color.
c GO analysis of protein coding genes in regions constitutively interacting with rDNA between wild type, premalignant, and malignant cells. Constitutively
interacting regions associated with protein coding genes (9382 unique genes, from Supplementary Data 2) were subjected to gene set over-representation
analysis using ConsensusPathDB (mouse) to identify enriched GO terms90–92, with p values referring to enrichment of the terms in the described dataset.
The genes contributing to these GOs include those encoding zinc finger domain, transmembrane channel and receptor proteins. p-value (x-axis) denotes
the significance of the number of interacting genes compared to the total number of genes in the GO classification. d Density histograms of gene
expression (RPKM) distributions for genes associated with regions that do interact (red line) and do not interact (blue line) with the rDNA in wild type,
premalignant and, malignant cells. Significance between groups was assessed using the nonparametric Kolmogorov-Smirnov (K-S) test. e Density
histogram of fold change (log2) in differentially expressed (DE) genes (premalignant vs. malignant) for all genes (including not interacting, black line) and
genes associated with significantly increased interactions (red line) and significantly decreased interactions (blue line) with the rDNA in malignant vs.
premalignant cells. Significance between increased and decreased interactions was assessed using the K-S test
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enriched peaks, and this increased two-fold to 27% (835 of 3,068
interactions) when we intersected UBTF-dependent rDNA class
switch interactions only (Supplementary Fig. 4b). H3K4me1 and
H3K4me3 are co-located at transcriptionally poised and/or active
genes64. Therefore, we intersected the H3K4me1 overlapping
rDNA class switch regions with identified H3K4me3 enriched
regions63. The majority (66% of 835) of the UBTF-dependent
rDNA class switch regions were enriched in H3K4me1 only,
while the remaining 34% were enriched for both H3K4me1 and
H3K4me3 (Supplementary Fig. 4b). In addition to its roles in
regulating Pol I transcription and rDNA chromatin status, UBTF
has also been shown to directly regulate a sub-fraction of Pol II
gene transcription65. Thus, we performed UBTF ChIP-
sequencing in the malignant progression setting to determine
whether UBTF is enriched at UBTF-dependent rDNA class
switch interaction regions. As previously reported65,66, the
majority of UBTF enrichment occurred at the promoter and
transcribed sequences of the rDNA repeat (Fig. 4b). We
intersected non-rDNA repeat UBTF-enriched peaks from pre-
malignant and malignant cells (Supplementary Data 7) with the
corresponding UBTF-dependent rDNA interaction regions and
found only ≤1% overlap (Fig. 4c). However, when we intersected
the nearest-located genes to UBTF peaks with those associated
with UBTF-dependent rDNA-interacting regions, we observed an
~10% overlap of genes in both premalignant and malignant cells
(Fig. 4c, Supplementary Data 7). While this degree of overlap
might, at least in part, reflect chance occurrence, it nonetheless
suggests the potential for UBTF loss to directly impact expression
of a small subset of rDNA class switch associated genes.
We performed GO analysis on the genes associated with rDNA
class switch interactions that exhibited either increased rDNA
interaction/decreased gene expression or conversely, decreased
rDNA interaction/increased gene expression (wild type to
malignant) during malignant transformation. B-cell differentia-
tion and lineage specification ontologies—including genes such as
Ebf1, Pbx1, and Runx1—were significantly enriched in the regions
that exhibited UBTF-dependent increased interaction and
decreased expression (Fig. 4d, Table 2 and Supplementary
Data 8). This observation is consistent with the established role
of compromised B-lineage-specific gene function in hematologic
malignancies via impaired differentiation67,68. Furthermore, the
regions that displayed UBTF-dependent decreased interaction
and increased expression were enriched in genes associated with
ribosome function, RNA processing/metabolism and mitochon-
drial/energy metabolism processes, e.g., Parn, Eif3d, Dhodh, and
Pdp2 (Fig. 4d, Table 3 and Supplementary Data 8). Both RNA
processing and mitochondrial function pathways are transcrip-
tionally regulated by oncogenic MYC and dysregulated during
malignancy41,42, and are consistent with GOs that were recently
identified as being enriched in rDNA Hi-C contacts detected in
human lymphoblastoid and leukemic cell lines69. These findings
reinforced the concept that UBTF-dependent changes in rDNA
interaction are associated with altered gene expression, potentially
through enhancer sequences located within the rDNA-interacting
fragments and, in a minor subset, through direct UBTF
regulation. Collectively, these results are consistent with a model
in which reformed rDNA-NAD interactions that occur with
UBTF-driven changes in rDNA chromatin during the transition
to B-cell malignancy coincide with gene expression changes that
impact specific functional pathways that promote the malignant
phenotype.
rDNA-interacting loci undergo nuclear re-localization. Our
results demonstrated that specific loci undergo altered interac-
tions with rDNA during malignant progression, which is asso-
ciated with differential gene expression (Fig. 3e). Such changes in
interaction frequency are likely the result of physical changes in
the relative positions of rDNA and the locus in question. To test
this, we measured the center-to-center distances between repre-
sentative interacting loci and the rDNA using dual-labeled 3D
DNA-FISH (3D-FISH)70 (Fig. 5, Supplementary Fig. 5). The
rDNA FISH specificity was validated by comparing its localiza-
tion with that of the rDNA-associated pre-rRNA processing
protein Fibrillarin (FBL) (Supplementary Fig. 5a). We measured
the distance between rDNA and Ebf1, a gene identified by 4C-seq
to have increased rDNA interaction in malignant vs. pre-
malignant cells, which is decreased upon Ubtf knockdown in
malignant cells. As predicted, the distance between Ebf1 and
rDNA decreased in malignant compared to premalignant cells
(representative images Fig. 5a, top; quantitation Fig. 5b, left)
while conversely, the distance increased in Eμ-Myc-shUbtf com-
pared to control cells (Eμ-Myc-LMP) (Fig. 5a, bottom; Fig. 5b,
right). The significant increase in interaction frequency
(decreased distance) between the Ebf1 locus and rDNA during
malignant progression was further validated by 3C-qPCR
(Fig. 5c). We also confirmed the opposite 4C-seq interaction









Gene description (GO term)
chr8:111250001–111255000 76.8 66.5 80.2 Zfhx3 zinc finger homeobox (metal ion binding)
chr7:87180001–87185000 73.7 70.5 55.5 Zfp710 zinc finger protein (metal ion binding)
chr2:62840001–62845000 99.7 61.5 72.0 Kcnh7 potassium voltage-gated channel (substrate-
specific channel activity)
chr11:48850001–48855000 62.3 70.5 77.1 Olfr56 olfactory receptor
chr15:95775001–95780000 64.4 95.3 86.4 Ano6 Ca2+ activated chloride channel (ion
transmembrane transporter activity)
chr8:41560001–41565000 72.7 52.6 80.2 Zdhhc2 zinc finger, DHHC-type containing (protein
modification process)
chr7:49120001–49125000 159.9 170.7 186.1 Vmn2r58 vomeronasal receptor
chr6:136000001–136005000 83.0 92.3 72.0 Grin2b NMDA ionotropic glutamate receptor
(transmission of nerve impulse)
chr1:87570001–87575000 76.8 85.3 97.7 n-R5s215 nuclear encoded rRNA 5S 215
chr12:92015001–92020000 76.8 63.5 126.5 n-R5s65 nuclear encoded rRNA 5S 65
chr13:20960001–20965000 145.3 127.0 170.7 Gm25605
(U1)
U1 spliceosomal snRNA
chr15:94530001–94535000 174.4 229.2 232.3 SNORA17 Small nucleolar RNA SNORA17
chr17:88855001–88860000 152.6 158.8 164.5 snoU13 Small nucleolar RNA U13
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Fig. 4 UBTF-dependent rDNA class switch interactions involve specific gene pathways. a Schematic illustrating the filtering workflow for identification of
UBTF-dependent rDNA-genome interactions that change from premalignant (prem) to malignant (mal) cells. Interactions that were not UBTF-dependent
or not identified in Eμ-Myc-LMP or Eμ-Myc-shUbtf cells were removed. b Integrated Genome Viewer screenshots of UBTF ChIP-seq enrichment at the
mouse rDNA repeat (one replicate shown), indicated by the schematic (top); ETS and ITS, external and internal transcribed spacers, respectively; IGS,
intergenic spacer; SP, spacer promoter; UCE, upstream control element; and CPE, core promoter element, along with the 18S, 5.8S, and 28S sequences
depicted. Below the schematic are ChIP-seq tracks from wild type (wt), premalignant, and malignant cells (set to display the same data range) with the
input control track shown at the bottom (data range adjusted for visualisation) and scale depicted underneath. c Intersection of UBTF-dependent rDNA-
NAD interactions with UBTF ChIP-seq. Venn diagrams indicating the overlap of UBTF-dependent rDNA-interacting regions (selected as shown in (a)) with
UBTF binding sites (top) and nearest associated unique genes for both sets of regions (bottom) in premalignant and malignant cells. d The enriched GO
terms were identified using standard DAVID analysis93,94, with p values referring to enrichment of the terms in the described datasets as in Fig. 3c. These
enriched ontologies include B-cell differentiation in UBTF-dependent increased interactions or ribosome metabolism and energy metabolism ontologies in
UBTF-dependent decreased interactions
Table 2 Increased rDNA class switch interacting regions
(window) in malignant compared to premalignant cells
corresponding to B-cell differentiation genes (decreased







chr16:35870001–35875000 2.829 −1.198 Parp14
chr11:33930001–33935000 1.892 −4.911 Lcp2
chr16:19925001–19930000 1.250 −1.850 Klhl6
chr11:44660001–44665000 0.909 −1.925 Ebf1
chr16: 92765001–92770000 1.514 −1.504 Runx1
chr11:44790001–44795000 0.443 −3.657 Il7r
chr19:34395001–34400000 0.751 −2.090 Fas
Table 3 Decreased rDNA class switch interacting regions
(window) in malignant compared to premalignant cells
corresponding to RNA metabolism or energy metabolism







chr14:55520001–55525000 −1.734 0.851 Pabpn1
chr17:56755001–56760000 −0.758 1.771 Rpl36
chr6:71885001–71890000 −0.719 2.377 Polr1a
chr15:77855001–77860000 −0.662 1.415 Eif3d
chr8:107125001–107130000 −2.623 0.980 Pdp2
chr8:112115001–112120000 −0.657 1.402 Dhodh
chr1:60380001–60385000 −0.118 1.621 Cyp20a1
chr3:97415001–97420000 −3.280 1.570 Chd1l
chr3:132755001–132760000 −1.026 1.770 Gstcd
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pattern, with 3D-FISH showing that the distance between the
Eif3d locus and rDNA increased during the premalignant to
malignant transition and decreased with UBTF knockdown
(Fig. 5d; Supplementary Fig. 5b shows additional 3D-FISH
assayed loci: Cyp51, Parn, Chd1l; Supplementary Fig. 5c shows
additional 3C-qPCR assayed loci: Pdp2 and Pbx1). 3D-FISH also
confirmed that no significant change in distance was measured
between the U1 small spliceosomal RNA gene and the rDNA in
either cell condition (Fig. 5e), consistent with its constitutive
association with the rDNA. Notably, some of the validated relo-
calized genes (e.g. Ebf, Pbx1) were also associated with UBTF
enrichment (Supplementary Data 7). Taken together, these results
demonstrate that malignant progression coincides with a subset
of specific loci that are ontologically associated with the malig-
nant phenotype undergoing a concurrent program of changes in
physical localization, rDNA interaction and gene expression, and
that these changes directly correlate with UBTF-mediated rDNA
class switching.
Discussion
We demonstrate that the rDNA chromatin state is decoupled
from rRNA transcription during the progression from pre-
malignancy to malignancy through a process of pseudo-silenced
rDNA activation that we term rDNA class switching. This
observation is consistent with the demonstration that rDNA
chromatin status does not strictly correlate with rRNA tran-
scription rates12,13. Indeed, complete loss of UBTF via condi-
tional deletion and subsequent eradication of the active rDNA
fraction is required before a significant impact on rRNA tran-
scription is observed17. Interestingly, the occurrence of rDNA
class switching during MYC-driven lymphomagenesis mirrors the
reverse observation as granulocytic cells undergo differentiation
accompanied by a reduction in MYC, which regulates UBTF
expression12,13,44. We speculate, given that MYC is dysregulated
in upwards of 70% of human cancers41,71, that rDNA class
switching is a more general mechanism underlying malignant
transformation.
Concomitant with rDNA class switching we observed a marked
repatterning of rDNA-NAD interactions. While chromosome
conformation capture techniques have previously identified
genomic regions associated with the rDNA28,62,72, the potential
dynamic regulation of rDNA-genome contacts and their func-
tional significance for disease are not well understood. Here we
demonstrate that as preneoplastic cells become malignant,
changes in the rDNA-interactome correlate with changes in
proximal gene expression, an observation supported by previous
reports that established a link between NAD-associated genes and
transcriptional repression24–27. Importantly, our findings identify
a subset of altered rDNA-interacting loci and their associated
gene expression changes that are dependent on UBTF-mediated
rDNA class switching. Elucidation of this dynamic rDNA inter-
action network in the Eµ-Myc cancer model revealed that rDNA
class switching is associated with functional consequences for
programs of Pol II transcriptional activity that are relevant to
malignant cell fitness.
rDNA class switching during the malignant transition is
accompanied by a significant increase in UBTF loading onto the
rDNA. We and others have shown that UBTF binding correlates
with psoralen accessibility12,17,57,73; however, UBTF alone is
unlikely sufficient to drive rDNA class switching. Specifically,
Ubtf knockdown does not significantly alter repressive chromatin
modifications and enforced Ubtf expression induces only a
modest increase in the proportion of active rDNA12. These
observations suggest that prior to association of UBTF, additional
epigenetic modifications occur at the rDNA that are required to
facilitate UBTF enrichment and rDNA class switching in malig-
nant cells.
We recently reported a link between UBTF and Pol II gene
transcription by identifying a role for UBTF at the promoters of
highly Pol II-transcribed genes65. Our genome-wide analysis of
UBTF enrichment in Eµ-Myc cells showed minimal overlap
(≤1%) between UBTF-bound (non-rDNA) sequences and the
rDNA-interacting regions that require UBTF (Fig. 4c). Moreover,
the rDNA class switch regions do not intersect with previously
identified UBTF-bound regions such as the histone gene clus-
ters65. However, when we extend the analysis to the nearest
associated genes, we observe that ~10% of these rDNA-
interacting loci are potentially regulated by UBTF. While fur-
ther investigation is required, these data suggest that UBTF does
not regulate Pol II genes directly through rDNA-interacting
regions, but may influence the expression of a small subset of the
UBTF-dependent rDNA-interacting genes either via proximity
while bound to rDNA or enrichment at these genes exclusive of
rDNA. Notably, several of the UBTF-enriched Pol II genes
(Supplementary Data 7) were validated by 3D-FISH and/or 3C-
qPCR to relocalize with respect to the rDNA during malignant
progression (e.g., Ebf1 and Pbx1). Thus, we propose that a
complex regulatory network including rDNA interactions and, in
some instances, direct UBTF regulation of Pol II gene tran-
scription, contributes to gene expression reprogramming during
malignant progression. Nonetheless, silencing Ubtf as a means to
reverse rDNA class switching revealed that the majority of
interactions rely on the altered rDNA state independent of UBTF
enrichment. Ongoing studies are focused on identifying factors
that directly mediate these dynamic rDNA interactions during
malignant transformation. The NoRC subunit TIP5/BAZ2A and
MYC mediate interactions between the rDNA and the nuclear
matrix74,75 while the chromatin regulatory factor CTCF interacts
with rDNA and is proposed to facilitate UBTF loading onto
rDNA, thereby contributing to the activation of silent rDNA
repeats57,66,72,76,77. The observed enrichment of the enhancer-
associated histone H3K4me1 modification at rDNA class switch-
dependent regions associated with altered gene expression sug-
gests a gene regulatory function for these interactions. Ultimately,
a comprehensive interrogation of these genomic loci via their
genetic disruption and the identification of their interacting
protein components will be required to elucidate their functional
significance.
MYC overexpression drives the Eμ-Myc premalignant pheno-
type, which we have characterized by increased rRNA tran-
scription of existing active rDNA repeats. We propose that
subsequent epigenetic events during the transition to malignancy
result in increased UBTF association with rDNA and rDNA class
switching. The question of whether the captured genomic inter-
actions occur with the active rDNA repeats only or also the silent
rDNA remains. Technical challenges preclude our ability to
directly address this question. However, it is predicted that the
malignancy-associated pronounced increase in active rDNA
coincides with altered physical properties of the rDNA chroma-
tin. Recent studies implicate a role for the biophysical properties
of phase separation between sub-nuclear compartments leading
to the nucleolar sequestration of certain proteins and driving
functional heterochromatin formation78–80. Another intriguing
consideration is that the epigenetic and/or transcriptional activity
of the rDNA might impact the transcriptional state of the
interacting genomic regions through titration of epigenetic
modifying or Pol II transcription factors.
Our results provide compelling evidence that the formation of
specific rDNA interactions contributes to transcriptional repro-
gramming of functionally relevant gene pathways. For example,
genes associated with increased rDNA interaction and decreased
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expression during malignancy are enriched for B-cell lineage and
differentiation genes, i.e., pre-B cell leukemia homeobox 1 (Pbx1),
Early B-cell Factor 1 (Ebf1), and Runx1. The dysregulation of
lineage-associated genes leads to impaired differentiation in
hematologic malignancies, such as acute leukemias and some
lymphomas67,68,81. While perturbation of differentiation or line-
age specification is often due to genetic alterations including
sequence mutation or chromosomal translocation, our findings
indicate that dysregulation of B-cell lineage genes can be influ-
enced by relocalization of genomic regions such as NADs. The
demonstration that a developmentally orchestrated nuclear re-
localization of the Ebf1 locus contributes to Ebf1 transcriptional
activation during B-cell differentiation82 corroborates such a
mechanism. Our data support a model where structural changes
in rDNA chromatin promote gene expression changes that
influence clonal selection of a malignant cell population.
Together, our data are consistent with the notion that the
rDNA repeats play a key regulatory role in cellular function
during disease development, independent of their role in deter-
mining ribosome content and growth rates. We propose that this
novel role is mediated through the formation and maintenance of
dynamic programs of spatial genome organization that regulate
distinct patterns of gene expression. Thus, developing tools to
target rDNA chromatin regulatory factors (such as UBTF) might
provide a therapeutic window in certain cancers. Previous studies
on Pol I transcription inhibitors as cancer therapies37,39,50,52
suggest that there are multiple mechanisms via which rDNA
transcription and chromatin may be targeted for therapeutic
benefit. If so, an increased fraction of active rDNA repeats may
function as a biomarker for the sensitivity of cancer cells to
inhibition of rRNA transcription.
Methods
Animal experiments and B-cell purification strategy. All animal experiments
were performed with approval from the Peter MacCallum Cancer Centre Animal
Experimentation Ethics Committee. Eμ-Myc mice were maintained as heterozygote
on a C57BL/6 background and monitored twice a week for lymphoma development.
Lymphomas can arise from expansion of either B220+/IgM− or B220+/IgM+
clones. Thus, to reduce the potential for variability in our study, we focused our
analysis on the IgM-negative B-cell subtypes sorted via flow cytometry from the
bone marrow niche from mice with normal B-cells, and from both premalignant
and fully malignant B cells obtained from Eµ-Myc mice, i.e., the B220high-
IgMlowIgDlow progenitor B (pro-B)/precursor B (pre-B) cells from premalignant Eµ-
Myc mice and their wild-type littermate controls, and the B220+IgM−IgD−
transformed pre-B cells from mice that have developed spontaneous disease
(malignant). Female mice were used for all wild type and premalignant cell col-
lections while both female and male mice were harvested for malignant cells due to
the spontaneous development of the lymphomas. Therefore, this strategy allowed us
to perform our experiments largely outside of variables due to differentiation and
tumor niche. Wild type and premalignant mice were sacrificed at age 4–6 weeks and
malignant mice as soon as they established spontaneous lymphoma (age
10–20 weeks).
Lymphoma cell line studies. For all in vitro experiments, the tissue cultured
adapted Eμ-Myc clone #4242 was used and maintained in Anne Kelso DMEM
supplemented with 10% fetal bovine serum (FBS), 100 mM L-asparagine (Sigma),
0.5% ß-mercaptoethanol, and penicillin/streptomycin/glutamine (GIBCO). A
stable Ubtf knockdown (the validated shUbtf hairpin37 targets both UBTF1 and
UBTF2 protein isoforms) cell line was generated in a 4242 Eμ-Myc line37 over-










































































































Fig. 5 rDNA class switch-dependent interacting loci undergo nuclear re-localization. a Representative 2D-FISH images taken from the 3D-FISH Z stack
images of nuclei depicting a decrease in distance between the early B cell factor 1 (Ebf1) gene (cyan, Alexa 488 signal; cyan arrows) and the rDNA
(magenta, Alexa 555 signal; magenta arrows) between premalignant (prem) and malignant (mal) cells. The distance decrease is reversed from LMP (Eμ-
Myc-LMP) to shUbtf (Eμ-Myc-shUbtf) cells. Nuclei were counterstained with DAPI (blue). Scale bars, 2 μm. b Boxplots of distances measured from 3D-
FISH analysis between the rDNA and the Ebf1 locus in premalignant (red) compared to malignant (gray) cells and LMP (blue) compared to shUbtf cells
(cyan). Distances between the closest two foci in each nucleus were measured using the Volocity software. Whiskers correspond to the 10th and 90th
percentiles of the data range, with data points outside this range not depicted. Significance was assessed using the Wilcoxon–Mann–Whitney test (*p-
value < 0.05, **p-value < 0.01, NS= not significant, n > average 170 distances). c 3C-qPCR validation of the increased interaction frequency between the
Ebf1 locus and the rDNA in malignant compared to premalignant cells. The interaction frequency was normalised to a single copy locus (Ercc3 gene) and a
multi copy locus (28S rDNA) and is represented as interaction frequency relative to premalignant cells (% of premalignant) (x ± s.e.m., *p-value < 0.05; n
= 3). Boxplots of distances measured from 3D-FISH analysis between the rDNA and the d eukaryotic translation initiation factor 3, subunit D (Eif3d) locus
between premalignant and malignant cells (increased distance) and reversed with Ubtf knockdown; and the e constitutively interacting U1 spliceosomal
snRNA (official MGI gene symbol, Gm25605) locus as described for b (***p-value < 0.001, ****p-value < 0.0001, n > average 170 distances)
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generated without BCL2 for GFP competition assay). Cells were retrovirally
transduced with shUbtf-MSCV-LTRmiR30-PIG or empty LMP retroviral vectors
(also shRrn3-MSCV-LTRmiR30-PIG for GFP competition assay; the shRrn3
hairpin was also previously validated37) (Open Biosystems) and transduced
populations selected by sorting for high GFP expression using flow cytometry. For
the GFP-based cell competition assays37, the indicated Eμ-Myc-LMP, Eμ-Myc-
shUbtf, or Eμ-Myc-shRrn3 cells were mixed with equal numbers of mock-
transduced (no vector) cells, cultured over 8 days and the percentage of GFP+ cells
determined by FACS. Eμ-Myc lymphoma cells were treated with 50 nm CX-5461
and NaH2PO4 vehicle for 1 h prior to harvesting for psoralen cross-linking and
qRT-PCR analysis.
3D DNA-FISH. Cells were fixed with 4% paraformaldehyde and cytospun on poly-
l-lysine-coated slides. Prior to hybridization, cells were permeabilized using 0.5%
Triton X-100 (20 min at room temperature), incubated in 20% glycerol for at least
1 h and subsequently freeze–thawed for three cycles in liquid nitrogen. Cells were
then treated with 0.1 N HCl (in 0.7% Triton X-100), incubated in RNase ONE
(Promega) for 30 min, dehydrated through a 70–80–100% ethanol series and
incubated in 50% formamide, 2 x SSC for at least 2 h prior to hybridization. Probes
were hybridized to pretreated slides at 85 °C for 2 min on a heat block and incu-
bated at 37 °C in a humidified chamber overnight. Post-hybridization washes were
performed at 42 °C in 2 x SSC/50% formamide followed by washes in 0.1 x SSC at
60 °C. Slides were incubated with Streptavidin-Alexa fluor 555 (Invitrogen) for
biotinylated probes or anti-digoxigenin Alexa fluor 488 (Invitrogen) for
digoxigenin-labeled probes. After washing, nuclei were counterstained using DAPI
and slides mounted with Prolong Gold antifade reagent (Invitrogen). Z-sections
were captured using a Nikon 90i eclipse microscope with equivalent exposure times
for all images. An average of more than 170 nuclei were analyzed for each probe
mix using the Volocity 3D image software (PerkinElmer) to measure center-to-
center distances. The individual populations (cyan signals for the interacting
regions and magenta signals for the rDNA) were detected separately and only spots
within the nucleus (as determined by the DAPI signal) were considered. Fur-
thermore, only cells in which both populations were present in the same nucleus
were used for further analysis. By defining the average cell size, individual cells
could be discriminated. All distances were measured from the centroids of each
population and the minimum distance for each spot selected for statistical analyses,
thus accounting for allelic differences.
Significance was assessed using the Wilcoxon–Mann–Whitney test. The BACs
used in the experiments were RP23–225M6 (rDNA), RP23–312-I5 (Ebf1),
RP23–443-E23 (Chd1l), RP23–16-E24 (Parn), RP23–407-C12 (Cyp51), RP23–449-
F4 (Eif3d), RP23–190-N22 (Pbx1), RP23–471-F21 (Pdp2), and RP23–448-J8 (U1).
For the generation of probes, BAC DNA was labeled by nick translation with
biotin-16-dUTP or digoxiginin-11-dUTP (Roche) using a nick translation kit
(Roche).
Psoralen cross-linking assay. Psoralen cross-linking12 was performed in isolated
nuclei that were irradiated in the presence of 10 μg/ml 4,5,8’-trimethylpsoralen
(Sigma–Aldrich). Genomic DNA was isolated and 10 μg was digested with SalI
(Promega). Fragmented DNA was separated on a 0.9% agarose gel, transferred
onto nylon membranes, and immobilized by UV irradiation at 1875 x 100 μJ/cm2
using a UV cross-linker (Stratalinker 2400; Agilent Technologies). The membrane
was hybridized with 32P-labelled rDNA (generated using a nick translation labeling
kit, Roche) and visualized on a PhosphoImager (GE Healthcare). Quantification
was performed using ImageQuant (TLv2005.04; GE Healthcare). Original psoralen
blot scans that correspond to quantitated and/or edited blot images shown in
Figs 1, 2 and Supplementary Fig. 2 are shown in Supplementary Fig. 1a, b and
Supplementary Fig. 8. A representative depiction of the psoralen blot quantitation
is shown in Supplementary Fig. 1c, d.
4C-library preparation. Chromatin libraries for 4C-seq were prepared as pre-
viously described83,84 and detailed here. Isolated wild type, premalignant and
malignant pre-B or harvested Eμ-Myc lymphoma cells (LMP and shUbtf), all
performed in two biological replicates, were crosslinked with 1% formaldehyde for
10 min, quenched with 125 mM glycine before being pelleted by centrifugation
(320g, 8 min, 4 °C). Cells were suspended in ice cold lysis buffer (10 mM Tris pH
8.0, 10 mM NaCl, 0.2% NP-40, protease inhibitor cocktail-EDTA-free (Roche)) and
lysed (10 min). Cell nuclei were collected by centrifugation (600g, 5 min, 4 °C),
supernatant removed, and nuclei resuspended in SDS (0.3% final conc., 1 h, 37 °C,
with shaking). Triton X-100 (1.8% final conc.) was added to sequester excess SDS
and the chromatin solution incubated (1 h, 37 °C, with shaking). Restriction buffer
(NEB) was added (1x final conc.) before the chromatin was digested with DpnII
(100 U, New England Biolabs, 37 °C, o/n, with shaking). DpnII was inactivated
(SDS [1.3% final conc.], 20 min, 65 °C) and the chromatin solution diluted (10-
fold) in water. Triton X-100 (1% final conc.) was added and the digested chromatin
incubated (1 h, 37 °C, with shaking) to sequester the unreacted SDS. As a control
for possible inter-molecular ligation events, an external DNA fragment from
Escherichia coli (E.coli K12 MG1655, sequence: 29555–29765) was added, at the
same concentration as a single copy locus, to each reaction. Fragments were ligated
using T4 ligase (20 U; Invitrogen) for 5h at 16 °C before being moved to room
temperature for 30 min Cross-links were reversed by the addition of proteinase K
(300μg) and incubation at 65 °C (overnight) before treatment with RNase A
(300μg, incubation at 37 °C for 1h). Ligation products were purified by phenol-
chloroform extraction and ethanol precipitation. For 4C-seq the DNA fragments
were amplified by PCR using inverse primers in the rDNA loci (Supplementary
Table 1) in the presence of two PCR blockers (Supplementary Table 2), which have
a C3 spacer at the 5’ and 3’end, located on either side of the specific restriction
fragments in the rDNA84. The PCR blockers inhibit elongation and thus amplifi-
cation of rDNA sequences85. By using PCR blockers, amplification of adjacent
fragments, caused by incomplete digestion or re-ligation of bait and adjacent
regions, will be avoided (see schematic, Supplementary Fig. 6). All primer
sequences are listed in Supplementary Tables 1 (bait primers) and 2 (blockers).
PCR products were mixed in equimolar ratios and sequenced on an Illumina
HiSeq2500 platform at Peter MacCallum Cancer Centre (150bp, paired-end).
4C-seq analysis. The sequencing reads were demultiplexed by splitting the reads
according to the 5’ bait sequence followed by computational removal of undigested
(or digested then re-ligated, both of which are minimized by PCR blockers, Sup-
plementary Fig. 6) or self-ligated reads. Bait sequences were trimmed using cuta-
dapt and the trimmed reads were aligned to the mm9 genome assembly
(ENSEMBL Mus musculus NCBIM37.67) using bowtie286 with default parameters.
Reads for which the bait sequences (up to the DpnII site) were not an exact match
were removed and thus interactions originating from 18S and 28S pseudogenes
were not considered for downstream analysis. Aligned reads were divided into non-
overlapping 5000-bp windows and the average read number calculated as semi-
quantitative measure of interaction frequency. To determine the expected inter-
action frequency relative to TSS a simulated dataset was generated by in silico
DpnII digestion, and analysed using the same parameters as for the real dataset
(Supplementary Fig. 7). The average distance to TSS was then calculated and
compared to the distance measured in wild type, premalignant, and malignant
cells. While we observed a similar overall distribution of interacting regions
compared with our dataset, our findings deviated in that we saw a greater
enrichment of regions around approximately 2kb upstream of the closest TSS, but
less so immediately at the TSS (Supplementary Fig. 7), corroborating the non-
random nature of our interactions.
To focus on rDNA interactions independent of bait location within the rDNA
repeat, we combined the reads for all bait sequences and removed interactions that
only appeared in less than four of the 11 bait sequences, and then the average read
number was calculated as semi-quantitative measure of interaction frequency.
Subsequently, the counts were normalized to the effective library size, which takes
the median of the ratio of the count for each gene to the geometric mean of the
counts as the scaling factor for each library (see Supplementary Data 1, raw and
normalized to effective library size provided). After removing a small number of
interactions that displayed very high interaction frequency in only one of the rDNA
bait sequences, all normalized interactions were mapped to each chromosome to
examine their distribution (Supplementary Figure 3a and b).
Differential interactions were determined using the normalized read count data
across replicates and applying a FDR cutoff (FDR ≤ 0.1). The R package DEseq was
used for differential interaction analysis. DEseq is considered more stringent than
EdgeR, calculating a scaling factor based on mean ratio, which has been shown to
perform better in regards to false-positives87. Non-differential interactions (no
significant change between wild type, premalignant, and malignant; FDR > 0.1), i.e.,
constitutively associated with the rDNA at all stages, were also identified
(Supplementary Data 2). We then focused on differential interactions between
premalignant and malignant cells (coincident with rDNA class switching,
Supplementary Data 4). Only interactions also identified in Eμ-Myc-LMP/Eμ-Myc-
shUbtf cells (Supplementary Data 5) were used for further analysis, allowing us to
identify and examine UBTF-dependent interactions. We categorized interactions
identified in the Eµ-Myc pre-B cells into those that increase upon transition from
premalignant to malignant and decrease in the absence of UBTF, and interactions
that decrease upon transition from premalignant to malignant and increase in the
absence of UBTF (Fig. 4a and Supplementary Data 6).
Interacting regions were visualized using circos plots88, which were generated
using the most significantly differential interactions, where interactions identified
in both replicates with one representative bait in the 28S rDNA (read counts > 10)
were selected and those with the highest interaction frequency, i.e., the top 10% of
interactions (232 in wild type, 493 in premalignant and 1546 in malignant), were
used to generate the circos plots. Comparisons of 4C-seq data and RNA-seq data
for associated regions were performed by displaying the RPKM distribution of
genes interacting and genes not interacting with rDNA as a kernel density estimate.
To compare differentially interacting regions with differentially expressed genes, all
differentially expressed genes between malignant vs. wild type and malignant vs.
premalignant (FDR ≤ 0.1, −0.5 ≥ logFC ≥ 0.5) were grouped into genes associated
with increased interacting regions and genes associated with decreased interacting
regions and the kernel density of fold change (log2) in expression estimated.
The SPRITE method interrogates crosslinked complexes of DNA segments in
physical proximity by marking all reads in a cluster (nuclear components that had
been crosslinked together) with the same barcode62. SPRITE reads were mapped
(mapq > 10) to NCBIM37.67 using Bowtie2 (v2.3.1) with the default parameters
(GEO: GSE114242). To find the concordance to our 4C data, we selected all
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clusters that included rDNA regions 18S and 28S and merged overlapping bins/
regions. We then compared the 4C interactions (5-kb bins, merged baits, and
replicates) to the regions containing SPRITE interactions. Using the R package
ChIPseeker (v1.8.6)89, we searched 100-kb up- and downstream of the SPRITE
peak (getTagMatrix with windows=SPRITE +/− 100 kb) and plotted the average
profile (plotAvgProf, 200-kb region) for the Eµ-Myc lymphoma cell lines (LMP,
shUbtf). For the bootstrap control analyses, SPRITE regions were replaced with the
same number (and size) of random regions from across the genome. The 4C
regions were then mapped to these random regions with the same parameters as
with the SPRITE-identified interactions (window size +/− 100 kb around the
random bootstrapped regions).
GO analysis was performed using ConsensusPathDB90–92 for the large set (9382
unique genes) of constitutive (between wild type, premalignant and malignant)
interacting regions and DAVID93,94 for the UBTF-dependent differential (between
premalignant and malignant) interacting regions. All statistical analyses were
performed using the R package (R team-Foundation for Statistical Computing
2010).
3C-qPCR. 3C libraries were prepared as described for 4C-seq but ending with the
extraction of DNA fragments. Quantification of ligated products was performed by
Taqman qPCR95. The primers used for 3C sample amplification are listed in
Supplementary Tables 3 and 4. Primer efficiency and ligation efficiency were
determined using randomly ligated BAC DNA containing genomic regions of
interest (BACs listed in 3D DNA-FISH methods), recommended as a control for
more reliable quantification in the context of complex mouse/human genomes96.
Further, we employed standard protocols for the generation of our control BAC
library95. Cross-linking frequencies were normalized to a single copy loci (Ercc3
gene) and multi copy loci (primer in 28S rDNA) (relative interaction frequencies
were determined by qPCR compared to standard curves as previously determined).
As internal control, the crosslinking frequency of fragments separated by 2 kb at
the Ercc3 gene was analysed97. Results were expressed as interaction frequency in
malignant cells relative to premalignant cells.
FACS analysis and sorting. The following antibodies were used for flow cyto-
metric analysis of cells isolated from bone marrow: APC-conjugated anti-B220/
CD-45R (eBioscience), fluorescein isothiocynate (FITC)-conjugated anti-mouse
IgM, and PE-conjugated anti-mouse IgD (BD Pharmingen). Stained cells were
resuspended in buffer containing 2 μmol/L FluoroGold (hydroxystilbamidine,
Molecular Probes, Invitrogen) before sorting on a FACSAria II flow cytometer (BD
Biocsiences, San Jose, USA).
RNA-FISH. Cells were fixed with 2% paraformaldehyde and cytospun on glass
slides. Slides were washed twice in 10% deionized formamide/2 x SSC, then
hybridized for 3 h at 37 °C in wash buffer containing 10% dextran sulphate,
50 μg/ml BSA, 500 ng/ml tRNA, and 10 μg/ml Cy3-conjugated RNA probe (Sigma)
complementary to part of the rapidly degraded ITS region (thus capturing rDNA
transcription rate) of the ribosomal DNA. The slides were then washed twice in
wash buffer, then three times in 0.1xSSC at 32 °C, before rinsing in PBS and
mounting in VectaShield containing DAPI.
rDNA methylation analyses. HpaII digestion and/or ChIP-CHOP assays12 were
performed by digesting genomic DNA or DNA isolated following UBTF ChIP with
HpaII before qRT-PCR. The relative amount of DNA resistant to HpaII digestion
was calculated after normalization to mock-digested DNA. The MeDIP assay was
performed as described12 by incubating 4 μg of sonicated single stranded (i.e., heat-
denatured) genomic DNA with 4 μg anti-5mC antibody for 2 h at 4 °C in 0.14 M
NaCl, 16.7 mM Tris, pH 8.0, and 0.05% Triton X-100. DNA-antibody complexes
were isolated with protein A-Sepharose beads (Millipore)/salmon sperm DNA for
2 h at 4 °C and following three washes, the DNA was eluted in 50 mM Tris, pH 8.0,
10 mM EDTA, and 0.5% SDS, then purified (including proteinase K digestion) and
analyzed by qRT-PCR. The percentage of bound DNA was calculated (subtracting
rabbit serum control) after normalization to 20 ng of input DNA. rDNA amplicon
primer sequences are listed in Supplementary Table 5.
RNA extraction and quantitative real-time PCR. RNA was isolated from sorted
pre-B cells using the NucleoSpin RNA extraction kit (MACHEREY-NAGEL).
cDNA was prepared and qRT-PCR was performed and normalized to B2M mRNA
levels44. qPCR analysis of rDNA transcription rates by assaying amplicons to
rapidly processed regions of the pre-rRNA was previously validated in Eμ-Myc cells
by comparison to [32P] orthophosphate pulse labeling followed by northern ana-
lysis, i.e., direct measurement via metabolic labeling of the newly synthesized
rRNA37. Primer sequences are listed in Supplementary Table 5.
ChIP and ChIP-seq. Standard UBTF ChIP was carried out as previously
described12,13. The polyclonal rabbit antiserum to UBTF1/2 was generated in-
house and ChIP amplicon primer sequences are listed in Supplementary Table 5.
ChIP-sequencing of UBTF-immunoprecipitated and input genomic DNA was
performed as previously reported65. In brief, libraries from two biological replicate
experiments (wild type, premalignant, and malignant cells) were prepared and
sequenced using the Illumina HiSeq2500 platform at Peter MacCallum Cancer
Centre. The 50-bp paired-end sequencing reads were mapped to the mouse gen-
ome database mm9 containing one copy of the rDNA (GenBank: BK000964.1)
using bowtie286 and duplicate reads were removed using the picard tool Mark-
Duplicates. Reads were visualized using the Integrative Genomics Viewer (IGV)98.
Peaks were called by the R package SPP99 and then used to perform an Irrepro-
ducible Discovery Rate (IDR) analysis100, which measures the consistency between
ChIP-seq replicates. Common peaks that passed the IDR reproducibility threshold
of <0.05 were annotated to the mouse genome (mm9) and used for further
intersection/comparison analyses. All analyses were performed using the default
options.
RNA-seq. Sequencing libraries were prepared from two biological replicate
experiments (wild type, premalignant, and malignant cells) using the TruSeq RNA
sample preparation kit (Illumina) and sequenced on an Illumina HiSeq2500
platform at Peter MacCallum Cancer Centre (50 bp, SE). The generated 50-bp
reads were aligned to the genome using TopHat v2.0.8b with default parameters
and the reads counted using HTSeq101. The differential expression between wild
type vs. malignant and premalignant vs. malignant was then calculated utilizing the
DEseq package102 in R (version 3.0.2) (R team-Foundation for Statistical Com-
puting 2010) and RPKM values calculated (see Supplementary Data 3). Only dif-
ferentially expressed genes with FDR ≤ 0.1 and −0.5 ≥ logFC ≥ 0.5 were considered
for further analysis.
Immunofluorescence. Immunofluorescence followed by rDNA FISH was per-
formed as previously described37,65. Briefly, cells were fixed in a 2% paraf-
ormaldehyde suspension, spun onto slides and stained with a fibrillarin (FLB)
antibody (Abcam, ab5821) followed by the 594-conjugated goat anti-rabbit IgG
secondary (Molecular Probe, A21442). Cells were fixed again with 4% paraf-
ormaldehyde and subjected to rDNA FISH (detailed in Methods, 3D DNA-FISH)
and then visualized on an Olympus BX-51 microscope, with images captured using
the SPOT Advance image acquisition software (Diagnostic Instruments).
Immunoblotting. Western blot analysis was performed with equal total protein
from whole cell lysate samples resolved by SDS-PAGE and transferred onto PVDF
membranes (Millipore). The in-house polyclonal rabbit antisera anti-UBTF1/2
antibody (also used for ChIP-seq) was detected following incubation with anti-
rabbit secondary antibody conjugated with horseradish peroxide (HRP) with
enhanced chemiluminescence (ECL) reagent (GE Healthcare).
Data availability
All data (4C-seq, RNA-seq and UBTF ChIP-seq) have been deposited in the NCBI
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
available under accession number GSE70226.
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